Actively Recruiting
Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
Led by Peking University Third Hospital · Updated on 2024-04-11
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of 18F-AlF-FAPI PET/CT scans to assess activity in patients with Thyroid Eye Disease (TED), a condition involving fibroinflammatory changes. This study aims to compare this newer imaging method with the traditional 99mTc-DTPA SPECT/CT scan to see which is better for diagnosing TED, monitoring therapy response, and following up with patients. The goal is to understand whether 18F-AlF-FAPI PET/CT provides superior diagnostic accuracy and useful information about disease activity. Participants with TED will undergo both 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT scans within a 10-day period. The scans measure uptake in the extraocular muscles using different metrics to evaluate disease activity. Researchers will analyze these imaging results alongside clinical data to assess how well each scan detects TED activity and responds to therapy changes. This process involves quantifying uptake using SUV metrics and uptake ratios for comparison. During the study, participants will be monitored for diagnostic accuracy and therapy response over an average of 6 to 12 months. Researchers will collect clinical information and imaging data to explore correlations between scan results and disease status. The study includes safety and follow-up assessments, with participants providing informed consent and cooperating with imaging procedures. The total involvement duration varies depending on follow-up needs.
CONDITIONS
Brief Title
Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with Thyroid Eye Disease
- Understands the study and voluntarily agrees to participate by signing informed consent
You will not qualify if you...
- Severe liver or kidney dysfunction
- Unable to lie on back for 5 minutes for examination
- Claustrophobia or other psychiatric disorders
- Pregnant, planning pregnancy, or breastfeeding
- Other conditions judged unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 10 days
Participants undergo 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT scans within a 10-day period to assess Thyroid Eye Disease activity.
2 visits (in-person)
Duration - Approximately 6 to 12 months
Participants are monitored for diagnostic accuracy and therapy response over approximately 6 to 12 months following scans.
Follow-up visits as scheduled by study team
Trial Site Locations
Total: 1 location
1
Dept. of Nuclear Medicine, Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
Actively Recruiting
Research Team
H
Hui Li, Dr.
L
Lingge Suo, Dr.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here